Prophylactic Breast Bud Radiotherapy for Patients Taking Bicalutamide: Should This Still Be Practised for Patients with Prostate Cancer? | Zendy

R. Lewis | Zendy; AM Cassoni | Zendy; H. Payne | Zendy

Open Access

Prophylactic Breast Bud Radiotherapy for Patients Taking Bicalutamide: Should This Still Be Practised for Patients with Prostate Cancer?

Author(s) -

R. Lewis,

AM Cassoni,

H. Payne

Publication year - 2012

Publication title -

case reports in oncological medicine

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.173

H-Index - 7

eISSN - 2090-6714

pISSN - 2090-6706

DOI - 10.1155/2012/239269

Subject(s) - bicalutamide , medicine , radiation therapy , breast cancer , tamoxifen , prostate cancer , oncology , hormonal therapy , hormone therapy , prostate , surgery , cancer , androgen receptor

Prophylactic breast bud radiotherapy is used to prevent gynaecomastia and mastalgia in patients with prostate cancer who are being treated with antiandrogen and oestrogen therapy. Here a case is presented of a patient who developed soft-tissue sarcoma of the breast subsequent to breast bud radiotherapy prior to bicalutamide hormone treatment. Bicalutamide is often prescribed for younger men in the adjuvant setting or as monotherapy for locally advanced disease. The data regarding the efficacy of prophylactic breast bud radiotherapy is reviewed, and it is proposed that alternative therapies should be considered such as tamoxifen.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research